Prospects of using the genetically engineered preparation dupilumab for the treatment of atopic dermatitis in the adult population
DOI:
https://doi.org/10.66344/jpad.v32i2.1900Abstract
Background Currently, the genetically engineered drug dupilumab, which was recently registered in Russia and is planned for use, is widely used in the world for the treatment of atopic dermatitis.
Objective Possibility of use of the genetically engineered drug dupilumab for the treatment of atopic dermatitis among adult population.
Methods To address the issues of treatment tactics in patients with atopic dermatitis, a 12-week placebo-controlled study of its effectiveness was carried out on two control groups of 45 people each, divided into three subgroups of 15 people (1 subgroup - placebo; subgroup 2 - dupilumab 300 mg subcutaneously 1 time in 2 weeks; subgroup 3 - dupilumab 200 mg subcutaneously 1 time per week). Evaluation of the effectiveness of the treatment of atopic dermatitis with the targeted drug dupilumab was carried out using the following scales: EASI, IGA, NRS, SCORAD, POEM, DLQI, HADS.
Results The results of the study show a significant improvement in the symptoms and manifestations of atopic dermatitis according to the SCORAD, EASI-70 and POEM scales. All patients taking dupilumab showed cleansing of the skin, a decrease in the intensity of pain and skin itching, which contributes to an improvement in the quality of life of patients with atopic dermatitis (a decrease in the DLQI value from 12-14 to 6-7), as well as a decrease in the level of anxiety and stress. At the same time, the number of side effects that occur in patients taking dupilumab and placebo is comparable.
Conclusion Based on the study and the results of earlier studies of the effectiveness of targeted therapy of atopic dermatitis with the genetically engineered drug dupilumab, it is possible to recommend a regimen for the use of this drug registered in the Russian Federation for the treatment of atopic dermatitis in the adult population: the initial dose of the drug is 600 mg, then 300 mg every 2 weeks with the regular use of moisturizers 2 times a day during the entire period of treatment. In the case of a protracted severe course of the disease, a weekly subcutaneous injection of the drug at a dose of 200-300 mg is possible.
References
1. Deckers IA, McLean S, Linssen S, Mommers M, van Schayck CP, Sheikh A. Investigating international time trends in the incidence and prevalence of atopic eczema 1990-2010: a systematic review of epidemiological studies. PLoS One. 2012;7(7):e39803.
2. Mathiesen S. M. & Thomsen S. F. The prevalence of atopic dermatitis in adults: systematic review on population studies. Dermatol Online J. 2019;25(8):13030/ qt6nj0x5k0.
3. Ring J., Alomar A., Bieber T., Deleuran M., Fink-Wagner A., Gelmetti C., Darsow U. Guidelines for treatment of atopic eczema (atopic dermatitis) part I. J Eur Acad Dermatol Venereol. 2012;26(8):1045-60.
4. Ring J., Alomar A., Bieber T., Deleuran M., Fink-Wagner A., Gelmetti C., Darsow U. Guidelines for treatment of atopic eczema (atopic dermatitis) part II. J Eur Acad Dermatol Venereol. 2012; 26(9):1176-93.
5. Saeki H., Nakahara T., Tanaka A., Kabashima K., Sugaya M., Muroto H., Katoh N. Clinical Practice Guidelines for the Management of Atopic Dermatitis. J Dermatol. 2016;43(10):1117-45.
6. Noda S., Krueger J. G. & Guttman-Yassky E. The translational revolution and use of biologics in patients with inflammatory skin diseases. J Allerg Clin Immunol. 2015;135:324-36.
7. Gittler J. K., Shemer A. & Suárez-Fariñas M. Progressive activation of T(H)2/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis. J Allerg Clin Immunol. 2012;130:1344-54.
8. Weidinger S. & Novak N. Atopic dermatitis. Lancet; 2016;387:1109-22.
9. Simpson E. L., Bieber T., Guttman-Yassky E., Beck L. A., Blauvelt A., Cork M. J., Ardeleanu M. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. New Eng J Med; 2016;375(24):2335-48.
10. Blauvelt A, de Bruin-Weller M, Gooderham M, Cather JC, Weisman J, Pariser D, Shumel B. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017;389:2287-2303.
11. Seegraber M., Srour J., Walter A., Knop M. & Wollenberg A. Dupilumab for treatment of atopic dermatitis. Expert Rev Clin Pharmacol. 2018;11(5):467-74.
12. Paller A. S., Bansal A., Simpson E. L., Boguniewicz M., Blauvelt A., Siegfried E. C., Gadkari A. Clinically Meaningful Responses to Dupilumab in Adolescents with Uncontrolled Moderate-to-Severe Atopic Dermatitis: Post-hoc Analyses from a Randomized Clinical Trial. Am J Clin Dermatol. 2020;21 Hosmer and Lemeshow test (1): 119-31.
13. Simpson E. L., Bieber T., Eckert L., Wu R., Ardeleanu M., Graham M. N., Mastey V. Patient burden of moderate to severe atopic dermatitis (AD): Insights from a phase 2b clinical trial of dupilumab in adults. J Am Acad Dermatol; 2016;74(3):491-8.
14. Gooderham M. J., Hong H. C. ho, Eshtiaghi P. & Papp K. A. Dupilumab: A review of its use in the treatment of atopic dermatitis. J Am Acad Dermatolo. 2018;78(3):28-36.
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Katerina Numerickaya, Mariya Riss
This work is licensed under a Creative Commons Attribution 4.0 International License.
Submission declaration
Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.
By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.
